Drug Information

Drug General Information
Drug ID
D04PUI
Former ID
DNCL003499
Drug Name
BT-062
Drug Type
Antibody
Indication Multiple myeloma [ICD9: 203; ICD10:C90] Phase 1/2 [522830]
Company
Biotest Pharmaceuticals; ImmunoGen
Target and Pathway
Target(s) Syndecan-1 Target Info [530195]
Pathway Interaction Database Beta3 integrin cell surface interactions
Integrins in angiogenesis
Proteoglycan syndecan-mediated signaling events
Syndecan-1-mediated signaling events
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
References
Ref 522830ClinicalTrials.gov (NCT01001442) Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 530195The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15;15(12):4028-37.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.